NMIBC
References:
- KEYTRUDA Prescribing Information.
References:
- Balar, A. V., Kamat, A. M., Kulkarni, G. S., Uchio, E. M., Boormans, . (2021). Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. The Lancet. Oncology, 22(7), 919–930.
References:
- NCCN guidelines: bladder Cancer. Version 1.2025 — March 25, 2025 (last accessed in 15.6.2025). available at : https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
KW-OMB-00004 | Exp 15 Jun 2027